Visa Q3 adjusted profit tops estimates on record cross-border volume growth
Reuters2026/07/28 20:14
Overview
U.S. digital payments firm's fiscal Q3 net revenue rose 14% yr/yr, driven by volume growth
Adjusted EPS for fiscal Q3 beat analyst expectations
Company repurchased $4.9 bln in shares during the quarter
Outlook
Visa did not provide specific guidance for the current or upcoming periods
Result Drivers
VOLUME GROWTH - Co said net revenue growth was driven by increases in payments volume, cross-border volume and processed transactions
CROSS-BORDER ACTIVITY - Cross-border volume excluding intra-Europe rose 12% yr/yr, supporting international transaction revenue
DATA PROCESSING REVENUE - Data processing revenue increased 17% yr/yr to $6.0 bln, contributing to overall revenue growth
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q3 Adjusted EPS |
Beat |
$3.32 |
$3.23 (30 Analysts) |
Q3 EPS |
|
$2.97 |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 42 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the business support services peer group is "buy"
Wall Street's median 12-month price target for Visa Inc is $410.00, about 13.1% above its July 27 closing price of $362.53
The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 22 three months ago
Reuters Recommended Reads
July 28 - Visa to lay off 7% of staff as efficiency push deepens
July 28 - PayPal presses on with turnaround in pivotal quarter as sale questions linger
July 28 - TransUnion beats Q2 revenue estimates, raises 2026 revenue growth outlook
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India
Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge
The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales
Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.
